Cargando…

SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus

Aberrant activation of the mTOR pathway is a characteristic alteration in triple-negative breast cancer, but the mTOR pathway inhibitor everolimus is not effective for the triple-negative breast cancer (TNBC) patients. Presently, we showed that the activation of ERK pathway was an important mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geng, Wenwen, Cao, Meiling, Dong, Ke, An, Junhua, Gao, Haidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177683/ https://www.ncbi.nlm.nih.gov/pubmed/37170083 http://dx.doi.org/10.1080/15384047.2023.2206362

Ejemplares similares

SHOC2 is associated with the survival of breast cancer cells and has prognostic value for patients with breast cancer
por: Geng, Wenwen, et al.
Publicado: (2020)

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts
por: Mercatali, Laura, et al.
Publicado: (2016)

The function of Shoc2: A scaffold and beyond
por: Jang, Eun Ryoung, et al.
Publicado: (2016)

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
por: Singh, Jasmeet Chadha, et al.
Publicado: (2014)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Jones, Greg G., et al.
Publicado: (2019)

miR-520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3-PTEN Axis in Breast Cancer
por: Geng, Wenwen, et al.
Publicado: (2020)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Functional Integration of the Conserved Domains of Shoc2 Scaffold
por: Jeoung, Myoungkun, et al.
Publicado: (2013)

Structural basis for SHOC2 modulation of RAS signalling
por: Liau, Nicholas P. D., et al.
Publicado: (2022)

Shoc2 recognizes bacterial flagellin and mediates antibacterial Erk/Stat signaling in an invertebrate
por: Zhao, Bao-Rui, et al.
Publicado: (2022)

Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer
por: Park, In Hae, et al.
Publicado: (2018)

Shoc2/Sur8 Protein Regulates Neurite Outgrowth
por: Leon, Gonzalo, et al.
Publicado: (2014)

Structure of the MRAS–SHOC2–PP1C phosphatase complex
por: Hauseman, Zachary J., et al.
Publicado: (2022)

Systematic identification of Celastrol-binding proteins reveals that Shoc2 is inhibited by Celastrol
por: Xiao-pei, Huang, et al.
Publicado: (2018)

Data set for transcriptional response to depletion of the Shoc2 scaffolding protein
por: Rouchka, Eric C., et al.
Publicado: (2016)

Fighting HIV-1 Persistence: At the Crossroads of “Shoc-K and B-Lock”
por: Acchioni, Chiara, et al.
Publicado: (2021)

Triple-negative breast cancer: understanding Wnt signaling in drug resistance
por: Merikhian, Parnaz, et al.
Publicado: (2021)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

The Role of the Tumor Microenvironment in Triple-Positive Breast Cancer Progression and Therapeutic Resistance
por: Pu, Qian, et al.
Publicado: (2023)

Drug Repurposing for Triple-Negative Breast Cancer
por: Ávalos-Moreno, Marta, et al.
Publicado: (2020)

Expanding the molecular spectrum of pathogenic SHOC2 variants underlying Mazzanti syndrome
por: Motta, Marialetizia, et al.
Publicado: (2022)

Gene Signatures and Cancer-Immune Phenotypes Based on m(6)A Regulators in Breast Cancer
por: Zhao, Guanghui, et al.
Publicado: (2021)

Role of SMC1 in Overcoming Drug Resistance in Triple Negative Breast Cancer
por: Yadav, Sushma, et al.
Publicado: (2013)

TGF-β induced reprogramming and drug resistance in triple-negative breast cells
por: Wu, Guoyu, et al.
Publicado: (2022)

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
por: Kimura, Mariko, et al.
Publicado: (2018)

Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer
por: Doddapaneni, Ravi, et al.
Publicado: (2017)

Role of eIF4A1 in triple‐negative breast cancer stem‐like cell‐mediated drug resistance
por: Raman, Dayanidhi, et al.
Publicado: (2020)

SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics
por: Boned del Río, Isabel, et al.
Publicado: (2019)

Correction: Systematic identification of celastrol-binding proteins reveals that Shoc2 is inhibited by celastrol
Publicado: (2021)

Repurposing of drugs for triple negative breast cancer: an overview
por: Spini, Andrea, et al.
Publicado: (2020)

Investigational Drug Treatments for Triple-Negative Breast Cancer
por: Damaskos, Christos, et al.
Publicado: (2021)

Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor
por: Rao, Zhou-Zhou, et al.
Publicado: (2023)

The long non‐coding RNA landscape in triple‐negative breast cancer
por: Zhang, Wenwen, et al.
Publicado: (2020)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
por: Vázquez, Ramiro, et al.
Publicado: (2016)

Ras and Calcium Signaling Pathways Converge at Raf1 via the Shoc2 Scaffold Protein
por: Yoshiki, Sayaka, et al.
Publicado: (2010)

Clinical Heterogeneity in two patients with Noonan-like Syndrome associated with the same SHOC2 mutation
por: Capalbo, Donatella, et al.
Publicado: (2012)

Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors
por: Yang, Fang, et al.
Publicado: (2016)

CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers
por: Cheriyan, Vino T., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hiig5dbnqc5fmo8m77rlim2k8k